Transcode Therapeutics, Inc. (RNAZ): Nasdaq/NYSE listing notice — Nasdaq Panel grants TransCode continued listing extension to Jan 22, 2024

Transcode Therapeutics, Inc.

Company must provide update on meeting stockholders' equity requirement by Nov 14, 2023 after Q3 10-Q filing.
By Jan 22, 2024, must demonstrate long-term compliance with Nasdaq's $2.5M stockholders' equity rule.
Panel cannot extend listing beyond Jan 22 if compliance not achieved; conditions may be reconsidered.
Company must promptly notify Nasdaq of any events that could affect compliance during exception period.
Previously received delisting determination after Staff rejected compliance plan; hearing held Oct 5, 2023.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Transcode Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5815(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5815(a)(2)

Exact text from the filing

October 26, 2023, the Company received written notice from Nasdaq (the “October Notification Letter”) that the Panel had granted the Company an exception from compliance with the Stockholders Equity Requirement and extension of continued listing until January 22, 2024, subject to the following: 1. On or before November 14, 2023, the Company shall provide a detailed update to the Panel regarding its meeting the Stockholders’ Equity Requirement; and 2. On or before January 22, 2024, the Company shall provide an update to the Panel on how it demonstrates long-term compliance with the Stockholders

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-112166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.